Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance

Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):501-6.


Aim: The aim of this study was to assess adiponectin, visfatin, HOMA-IR, glucose and triglyceride levels in term, preterm and extremely low birth weight (ELBW) babies. Each of these three groups was subdivided into two groups as small-for-gestational age (SGA), and appropriate-for-gestational age (AGA). 30 term, 30 preterm and 30 extremely low birth weight infants were included into the study.

Results: There was no significant difference in term and preterm infants for serum adiponectin, visfatin, and HOMA-IR levels. There were also no significant differences between term and preterm infants for glucose and triglycerides. The serum visfatin, insulin and HOMA-IR levels (p = 0.001, p = 0.001 and p < 0.05, respectively) were higher in ELBW group than preterm group. Comparing the subgroups as SGA and AGA in all main groups, only in ELBW group there were no significant differences in serum adiponectin, visfatin, HOMA-IR and insulin levels.

Conclusions: We suggest that visfatin can be used as an early indicator of insulin resistance. Independent of being SGA, ELBW itself may be a risk factor for insulin resistance. In the follow-up of these babies the risk of obesity, metabolic syndrome and cardiovascular diseases may be increased as in SGA babies.

MeSH terms

  • Adiponectin / blood*
  • Biomarkers / blood
  • Blood Glucose / analysis
  • Case-Control Studies
  • Cytokines / blood*
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight / blood*
  • Infant, Newborn
  • Infant, Small for Gestational Age / blood*
  • Insulin / blood
  • Insulin Resistance*
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Risk
  • Triglycerides / blood


  • Adiponectin
  • Biomarkers
  • Blood Glucose
  • Cytokines
  • Insulin
  • Triglycerides
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human